What are the side effects of immunotherapy for Triple-Negative Breast Cancer

Side Effects of Immunotherapy for Triple-Negative Breast Cancer

Immunotherapy is an important treatment option for triple-negative breast cancer (TNBC), particularly when combined with chemotherapy. Let me explain what side effects patients should be aware of.

How Immunotherapy Works (And Why Side Effects Occur)

Immunotherapy drugs—specifically PD-L1 inhibitors like pembrolizumab—work by "releasing the brakes" on your immune system so it can recognize and attack cancer cells. However, because your immune system becomes more active overall, it can sometimes attack healthy cells and tissues in your body. This is why immunotherapy side effects are called immune-related adverse events (irAEs).

Common Immunotherapy Side Effects for TNBC Patients

According to NCCN Guidelines, patients receiving immunotherapy should be screened for and managed for:

Endocrine (Hormone) Dysfunction

• Hypothyroidism (underactive thyroid) - the most common endocrine side effect
• Adrenal insufficiency (when your adrenal glands don't produce enough hormones)
• These require blood tests to monitor and may need hormone replacement therapy

Other Immune-Related Side Effects (General Categories)

While the NCCN Guidelines emphasize that comprehensive toxicity management is essential, common immune-related side effects can include:

• Skin reactions - rashes, itching, or other skin changes
• Gastrointestinal issues - diarrhea, nausea, or colitis (inflammation of the colon)
• Lung problems - pneumonitis (inflammation of lung tissue)
• Liver inflammation - elevated liver enzymes
• Joint and muscle pain
• Fatigue

Important Context for TNBC Specifically

According to NCCN Guidelines for Triple-Negative Breast Cancer, pembrolizumab combined with chemotherapy is a Category 1 (preferred) first-line treatment for patients with PD-L1 CPS ≥10. This means the benefits typically outweigh the risks for eligible patients, but careful monitoring is essential.

Monitoring and Management

The NCCN Guidelines emphasize that:

• Regular screening for immunotherapy-related toxicities is mandatory
• Patients should report new symptoms immediately to their care team
• Most side effects can be managed effectively with appropriate treatment
• Some side effects may require temporarily pausing or stopping immunotherapy

Questions to Ask Your Oncology Team

1. Which specific immunotherapy drug are you recommending, and what are MY individual risk factors for side effects?
2. How will you monitor me for immune-related side effects? What tests and how often?
3. What symptoms should I report immediately versus those I can manage at home?
4. If I develop side effects, what are my options? Can we manage them, pause treatment, or switch approaches?
5. Will I need hormone replacement therapy or other supportive medications?
6. How long will I receive immunotherapy, and what happens after treatment ends?

The Bottom Line

Immunotherapy side effects are real and require active management, but they're often manageable with proper monitoring and medical support. For many TNBC patients—especially those with PD-L1 positive tumors—the survival benefits of immunotherapy combined with chemotherapy make it a worthwhile treatment option. Your oncology team will work with you to catch and manage side effects early.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.